Navigation Links
Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
Date:7/20/2011

ulus' intellectual property estate contains both the fundamental and core patents in the field and includes over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In April 2008, Regulus formed a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. In February 2010, Regulus and GlaxoSmithKline entered into a new collaboration to develop and commercialize microRNA therapeutics targeting microRNA-122 for the treatment of hepatitis C infection. In June 2010, Regulus and sanofi-aventis entered into the largest-to-date strategic alliance for the development of microRNA therapeutics. This alliance is focused initially on fibrosis. For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding the future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus. Any statement describing Regulus' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Such forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause the results to differ materially from those expressed or implied by such forward-looking statements. Although these forward-looking statements reflect the good faith judgment of Regulu
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
5. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
6. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
11. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has announced ... - Growth, Trends & Forecasts (2014-2020)" report to ... market is estimated at $0.17 billion by 2018 at ... The near future will bring Biomedical sensors that ... These sensors can be set to trigger alerts when ...
(Date:8/31/2015)...  For people with Down syndrome, news from ... company, located in the Science + Technology Park at ... therapies yet for people with Down syndrome and other chromosome ... syndrome and Edwards syndrome aneuploidies in human cell cultures, ... Elixirgen plans to develop this technology into a treatment ...
(Date:8/31/2015)... SHANGHAI , Aug. 31, 2015  MicuRx ... antibiotics, today announced positive top-line results from the ... drug candidate MRX-I. MRX-I is an oral oxazolidinone ... MRSA and VRE, while offering physicians and patients ... currently available oxazolidinone agents. "These ...
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies ... the drug development approval process. Thus, innovator companies must understand what will be ... a Chicago-based CMO, has been hosting multiple educational panels and seminars for experts ...
Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... Mich., April 16 Lycera Corp. today announced it ... which is developing novel small-molecule pharmaceuticals to treat autoimmune ... has received $10 million as a first tranche of ... proceeds in two tranches as specific milestones are met. ...
... Bioscience Inc have successfully implemented Amphora,s PatentSafe solution ... using PatentSafe as a fully electronic lab notebook, ... more efficiently into today,s laboratories but it also ... simply and effectively, saving significant time previously spent ...
... One,Medical, Inc. ("China Sky One Medical" or "the Company") ... company producing over-the-counter,drugs in the People,s Republic of China ... and fiscal year ended December 31,2008. , , ... -- Total revenues increased 104.0% year-over-year to $26.0 million, ...
Cached Biology Technology:Lycera Closes $36 Million Series A Financing 2Lycera Closes $36 Million Series A Financing 3Lycera Closes $36 Million Series A Financing 4Solidus Bioscience Protect their Research and Improve Efficiency With Amphora's PatentSafe Solution 2Solidus Bioscience Protect their Research and Improve Efficiency With Amphora's PatentSafe Solution 3China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 2China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 3China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 4China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 5China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 6China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 7China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 8China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 9China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 10
(Date:8/25/2015)... and BELLEVUE, Wash. , ... in advanced robotic systems, announced today it will unveil ... ground vehicle (UGV), at the National Tactical Officers Association ... The Guardian S is the first-ever commercially ... of years of research and in-field trials and is ...
(Date:8/20/2015)... Calif. , Aug. 20, 2015   ... focused on improving the user experience and security ... vision technologies, today announced that its TrulySecure™ ... biometric authentication software to be FIDO Certified™. ... TrulySecure for compliance with the FIDO UAF (Universal ...
(Date:8/18/2015)... , Aug. 17, 2015 Research ... addition of the "Global Biometric Authentication & ... - Estimation & Forecast, 2015-2020" report to ... authentication and identification systems market is expected to ... 2015 to 2020 and generate over $25 billion ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... of two tiny marine algae, a team of scientists ... research in algal physiology, plant biology, and marine ecology. ... Monterey Bay Aquarium Research Institute (MBARI) and the Joint ... effort between MBARI, JGI, and an international consortium of ...
... CREEK, Calif. Scientists from two-dozen research organizations led by ... (JGI) and the Monterey Bay Aquarium Research Institute (MBARI) ... genes enabling them to capture carbon and maintain its ... a team led by Alexandra Z. Worden of MBARI ...
... North Carolina at Chapel Hill School of Medicine have identified ... the most deadly types of cancer, and discovered how a ... and potential treatment apply to a type of brain tumor ... larger group of brain tumors called malignant gliomas, which is ...
Cached Biology News:Genes from tiny marine algae suggest unsuspected avenues for new research 2Genes from tiny marine algae suggest unsuspected avenues for new research 3Genes from tiny marine algae suggest unsuspected avenues for new research 4Genes from tiny algae shed light on big role managing carbon in world's oceans 2Genes from tiny algae shed light on big role managing carbon in world's oceans 3UNC study: Scientists identify chemical compound that may stop deadly brain tumors 2
...
... the first biological reagent that ... and not just by inhibiting ... anti-mycoplasma agent that can be ... directly. The cytotoxicity of Mynox ...
... can be used to label ... covalently bound acridinium NHS ester ... presence of hydrogen peroxide. Acridinium ... used as a detection method ...
... mobility shift assay (EMSA) is a powerful ... to as gel shift or gel retardation, ... that when subjected to electrophoresis, free DNA ... The Pierce LightShift Chemiluminescent EMSA Kit is ...
Biology Products: